In patients with high DLL3 expression (DLL3 expressed by > 75% of tumor cells by IHC), the ORR was slightly higher at 14.3%, with a median progression-free survival (PFS) of 3.8 months and a median OS of 5.7 months. The gene discussed is DLL3; the disease is neoplasm.